In particular, the expression levels of RETNLB were found to decrease significantly in subjects mutated for the TP53 and BRAF genes, while they increased in subjects mutated for KRAS, all compared to wild-type CRC patients. This evidence concerns the gene TP53 and colorectal carcinoma.